THE SOFIX HEALTH AND A INNOVATIVE PEPTIDE BLEND |

Latest studies suggest Sofix’s's Cagrilintide/GLP-1 offers a distinctive therapeutic strategy for targeting glucose-related disorders. This peptide mixture merges Cagrilintide, a targeted GLP-1 receptor stimulator, with a established GLP-1 analogue. The potential synergistic outcome could lead to